Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oramed Pharmaceuticals, a developer of alternative drug delivery systems, has concluded a proof of concept study in South Africa of insulin suppositories, ORMD-0802, using its proprietary technology.
Subscribe to our email newsletter
Approximately eight healthy volunteers came for two visits, with two different formulations. The insulin suppositories showed rapid insulin absorption and reactive glucose lowering effect. The suppositories were well tolerated and no adverse events were encountered, the company said.
Oramed’s insulin suppositories are advanced as a treatment alternative for injectable insulin. Such an alternative may be especially useful for individuals with immunological-based reactions to repeated injections and who require a temporary recess from daily injections, the company added.
Nadav Kidron, CEO of Oramed, said: “This proof of concept study of ORMD-0802, insulin suppository, was an important milestone in using our proprietary technology to expand our product pipeline.”